In the PROBASE study (Risk-adapted prostate cancer early detection study based on a “baseline” PSA value in young men – a prospective multicenter randomized trial) a modern concept of a general PSA-Screening will be investigated. However, the optimal age to begin a risk-adapted PSA screening with screening intervals according to the level of the individual baseline PSA value has never been evaluated in a prospective randomized trial. The present trial is the first randomized trial to prospectively evaluate the concept of a baseline PSA. Furthermore, it is the first trial to define the beginning of a risk-adapted screening either at age 45 or 50. In addition, this trial will evaluate subsequent risk-adapted screening intervals according to the level of the individual baseline PSA value.
Amount of probands:
Temperatur of storage: